FDA Grants Lete-cel BTD in Myxoid/Round Cell Liposarcoma
The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.
Related Articles
Clinical Trials Are Testing Ways to Prevent Breast Cancer
At the 2024 San Antonio Breast Cancer Symposium, researchers discussed clinical trials for vaccines and other ways to prevent breast cancer.
Call for EIC – CA: A Cancer Journal for Clinicians – Wiley Online Library
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
APCCC Diagnostics 2025 – APCCC
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid…
Fundamentals of HCT Training Course
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
Cell Proliferation: Vol 58, No 1
Cell Proliferation is an open access cell biology journal covering stem cells, cancer, regenerative medicine, tissue engineering, cell cycle control, cell senescence & death, and…
RP1 Combination Shows Response, Safety in Advanced Melanoma
Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.
Lower-intensity therapy for good-risk B-ALL
In this issue of Blood, Purvis et al1 have demonstrated that most children with B-lineage acute lymphoblastic leukemia (B-ALL) within the good-risk categor
Treatment of Pleural Mesothelioma: ASCO Guideline Update
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the…
FDA Grants Orphan Drug Designation to ELC-100 in Pancreatic NETs
Investigators are assessing treatment with ELC-100 among patients with pancreatic neuroendocrine tumors as part of a phase 1/2 trial.
